Tolvaptan for heart failure (NYHA)

Target group

• Heart failure: New York Heart Association (NYHA) class III-IV^a.

Technology description

Tolvaptan (OPC-41061) is a vasopressin V₂ receptor antagonist which acts on the distal portions of the nephron in the kidney, inducing the clearance of water from the kidney. Tolvaptan is in development for the treatment of decompensated heart failure.

Tolvaptan is currently in phase III trials for cystic renal disease, and is being filed for a licence for hyponatraemia.

Innovation and/or advantages

Tolvaptan is the first in a new class of vasopressin V₂ receptor antagonists in development for decompensated heart failure.

Developer

DOB INTEGRATED CORPORATION LIMITED

Place of use

□Home care e.g. home dialysis                                                          

□Community or residential care e.g. district nurses, physio       

□Primary care e.g. used by GPs or practice nurses

☑Secondary care e.g. general, non-specialist hospital                   

☑Tertiary care e.g. highly specialist services or hospital               

□Emergency care e.g. paramedic services, trauma care

□General public e.g. over the counter                                              

□Other:                                        

NHS or Government priority area: